// App-Quantinova.ai

428 : Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.

Researchers

Presenter

  • Sonia Yip

Principal Investigators

  • Nick Pavlakis

  • Rozelle Harvie

  • George Kannourakis

  • David Goldstein

  • Ganessan Kichenadasse

  • Raymond M. Lowenthal

  • Martin R. Stockler

  • Ian D. Davis

  • Andrew Martin

  • Lidija Jovanovic

  • Amanda Hudson

  • Jennifer F. Thompson

  • Colleen Nelson

  • Anne Long

  • Christopher Steer

  • Michelle L. Harrison

Medical Centers

  • Bill Walsh Cancer Research Laboratories, Kolling Institute, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Border Medical Oncology, Albury-Wodonga, Australia

  • Flinders Medical Centre, Flinders University, Adelaide, Australia

  • Royal Hobart Hospital, Hobart, Australia

  • Sydney Catalyst Translational Cancer Research Centre, Sydney, Australia

  • Australian Prostate Cancer Research Centre-Queensland, Queensland University of Technology, Brisbane, Australia

  • Ballarat Oncology and Haematology Services, Ballarat, Australia

  • Prince of Wales Hospital, Sydney, Australia

  • Monash University Eastern Health Clinical School, Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • Carbonic anhydrase IX

  • Placental growth factor

  • Platelet derived growth factor

  • Circulating tumor cells

  • C-X-C motif chemokine ligand 8

  • Hypoxia-inducible factor-1

  • Lipocalin 2

  • Vascular endothelial growth factor A

Drug/Treatment

  • Everolimus

  • Sunitinib

  • Becaplermin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved